Extended survival in a case of metastatic choroidal melanoma with immunotherapy

Mirzayev I., GÜNDÜZ A. K., Mirzayeva L., CEYHAN K.

Anti-Cancer Drugs, cilt.35, sa.10, ss.974-978, 2024 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 35 Sayı: 10
  • Basım Tarihi: 2024
  • Doi Numarası: 10.1097/cad.0000000000001650
  • Dergi Adı: Anti-Cancer Drugs
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, Biotechnology Research Abstracts, CAB Abstracts, Chemical Abstracts Core, EMBASE, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.974-978
  • Anahtar Kelimeler: choroidal melanoma, immunotherapy, ipilimumab, liver metastasis, nivolumab, survival, uveal melanoma
  • Ankara Üniversitesi Adresli: Evet

Özet

Uveal melanoma is the most common intraocular malignancy in adults. Despite advances in local treatments, approximately 50% of all cases eventually die from metastatic disease. In cases with metastasis, 2-and 5-year survival rates are approximately 10% and <1%, respectively. Advances in molecular biology have led to the identification of a number of promising drugs including immune checkpoint inhibitors (ICIs). Ipilimumab and nivolumab are ICIs targeting the cytotoxic T-lymphocyte-Associated antigen-4 and the programmed-cell death protein-1, respectively. Herein, we present a case of choroidal melanoma having liver metastasis treated with nivolumab and ipilimumab and transarterial radioembolization, achieving a 3-year survival.